Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: The increased rates of both overweight and obesity reported in severely mentally‐ill patients are prevalently due to the use of second‐generation antipsychotics (SGAs). Hence, the main purpose of this article is to analyze systematically potential patient‐ and drug‐related factors which may increase the risk of weight gain during long‐term treatment with such medications. Literature information published in English since 1966 and last updated on 17 January 2009 was identified through different databases and using various combinations of search terms. Searches provided 242 articles, whereas 6 additional references were identified manually. Peer‐reviewed articles focusing on the risk of weight gain during SGA‐chronic treatment (at least 52 weeks, N = 81) were acquired. Data were extracted from the 39 peer‐reviewed articles which investigated factors potentially associated with an increased risk of this event. Evidence‐based information suggests that a number of factors, either patient‐ (age, baseline BMI/bodyweight, recent onset of psychotic episodes, need of concomitant psychotropic medications) or drug‐specific (relative receptorial affinity, timing of weight changes plateau, daily dose, iatrogenic concomitant changes in biochemical metabolic parameters) may contribute to increase either rates and/or magnitude of this effect during long‐term treatments with specific SGAs. All contributors and their relationship with specific drugs should be taken into consideration when designing a long‐term therapy with SGAs. Among the best studied agents (clozapine, olanzapine, and risperidone) of this class, the latter seems to be the most susceptible drug to the amplifying effects of both patient‐ and drug‐related factors on the risk of inducing weight changes during chronic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“Despite it being stated that the advent of second generation of antipsychotics (SGAs) has been one of the greatest advances in the pharmacology of mental disorders over past decades (8), the concerns that this class of drug is likely to induce weight gain have been recognized since the late 1990s (9).”
BackgroundCause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542
The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Klok, M. D., Jakobsdottir, S., & Drent, M. L. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00270.x · Cited by 1,442
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Keck, P. E., & Calabrese, J. R. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1003 · Cited by 238
Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain
Nemeroff, C. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0506 · Cited by 86
Cited by
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
BackgroundPharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
Lett, T. A. P., Wallace, T. J. M., Chowdhury, N. I., Tiwari, A. K., Kennedy, J. L., & Müller, D. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.109 · Cited by 264
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Drug treatment for mood disorders in pregnancy
Gentile, S. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283413451 · Cited by 60
Self-citation
Metadata
- Authors
- Gentile, S.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2009-08-26
- Volume
- 10
- Issue
- 5
- Pages
- 527-542
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2160351074
- Cited by
- 61
- References
- 7
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications. https://app.cochat.ai/papers/10.1111/j.1467-789x.2009.00589.x
- The paper
- Gentile, S. (2009). Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications. Obesity Reviews. https://doi.org/10.1111/j.1467-789x.2009.00589.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.